Alacizumab pegol
Alternative Names: CDP-791Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator UCB
- Class Antineoplastics; Monoclonal antibodies; Polyethylene glycols
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 13 Sep 2011 No development reported - Phase-II for Non-small cell lung cancer in Hungary (IV)
- 13 Sep 2011 No development reported - Phase-II for Non-small cell lung cancer in Poland (IV)
- 13 Sep 2011 No development reported - Phase-II for Non-small cell lung cancer in Russia (IV)